Skip to main content
OpenTrials
Recruiting

NCT Number: NCT01808937

Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository

The Morphea in Adults and Children (MAC) cohort is the first registry for both children and adults with morphea (also known as localized scleroderma) in the country. The purpose of the registry is to learn more about morphea, specifically:

* How morphea behaves over time * How frequently specific problems occur along with morphea (for example, arthritis) * Whether morphea has an autoimmune background

Recruiting

Interested in participating?

Request Info

Key information

Age range

Up to 90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

UT Southwestern Medical Center - Department of Dermatology

Dallas, Texas, 75390-9069, United States

Location status: Recruiting

Location contact

Heidi Jacobe, MD, MSCS

CONTACT

[email protected]

214.633.1837

Heidi Jacobe, MD, MSCS

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient must have a clinical diagnosis of morphea confirmed by the primary investigator and by histopathological examination.
  • Ages 0-90 years old
  • Children must weigh more than 20 lbs. in order to satisfy Children's Medical Center policy for the maximum amount of blood drawn in a 24 hour period.
  • Patient or legal guardian must be able to speak and read at a 6th grade reading level.
  • Both male and female patients will be eligible
  • All races and ethnic backgrounds will be included
  • Relationships to proband: All patients with morphea will be included. A patient's family history will be reviewed and if there is a family history of morphea or systemic sclerosis then we will give the study patient the investigator's contact information and ask the family member to call the study team to answer any questions and enroll them in the study if they choose to do so.
  • Ability to give informed consent: Patients must be able to give informed consent or they will give assent with parent or guardian consent as a minor to be a part of the morphea registry.

Exclusion criteria

  • Patients who have been coded as morphea (701.0), but do not have morphea/localized scleroderma (examples: steroid atrophy, acquired keratoderma, keloids, nephrogenic fibrosing dermopathy, systemic sclerosis, lichen sclerosis)

Treatment and study plan

Morphea

Other

Other names: Scleroderma, Localized, Scleroderma, Circumscribed, Scleroderma, Linear, Frontal Linear Scleroderma en Coup de Sabre

Primary outcomes

  1. Activity/damage measurement in morphea as scored on the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT)

    Time frame: 5 years

Secondary outcomes

  1. Quality of life scores measured by the Dermatology Life Quality Index (DLQI)

    Time frame: 5 years

Study contacts

Contact information is provided by the study sponsor or research team.

Heidi Jacobe, MD, MSCS

CONTACT

[email protected]

214.633.1837

Sponsors and collaborators

Lead sponsor

University of Texas Southwestern Medical Center

Other

Registry information

Official study title

Immunologic and Genetic Profiles in Subsets of Morphea Patients

Acronym: MAC

Important dates

Study start
2007
Primary completion
2027
Study completion
2028
First posted
Mar 11, 2013
Registry last updated
May 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.